Opinion|Videos|August 15, 2024

Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

Author(s)Gordon Lam, MD, Leonard Calabrese, DO, Grace Wright, MD, PhD

A panel of medical experts discuss complications and prognostic factors in uncontrolled rheumatoid arthritis.

Episodes in this series

EP. 1 Intro and Welcomes

EP. 1 Intro and Welcomes

EP. 2 Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission

EP. 2 Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission

EP. 3 Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice

EP. 3 Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice

EP. 4 Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

EP. 4 Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

EP. 5 Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP. 5 Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP. 6 Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments

EP. 6 Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments

EP. 7 Achieving Low Disease Activity and Remission: Managing Patient Expectations

EP. 7 Achieving Low Disease Activity and Remission: Managing Patient Expectations

EP. 8 Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

EP. 8 Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

EP. 9 Advanced Treatment Options for RA: Exploring the Data

EP. 9 Advanced Treatment Options for RA: Exploring the Data

EP. 10 Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons

EP. 10 Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons

EP. 11 JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

EP. 11 JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

EP. 12 JAK Inhibitor Selectivity and Dose-Related Toxicity

EP. 12 JAK Inhibitor Selectivity and Dose-Related Toxicity

EP. 13 Outcomes of Class Switching vs Cycling TNF Inhibitors

EP. 13 Outcomes of Class Switching vs Cycling TNF Inhibitors

EP. 14 Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices

EP. 14 Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices

EP. 15 Safety and Efficacy of Janus Kinase Inhibitors

EP. 15 Safety and Efficacy of Janus Kinase Inhibitors

EP. 16 Closing Remarks

EP. 16 Closing Remarks

Video content above is prompted by the following:

What are typical complications associated with uncontrolled rheumatoid arthritis?

Are there patient prognostic factors that can help determine likelihood of uncontrolled disease vs remission?

Related Content

Q4 2025 Recap: Rheumatology News and Updates

Q4 2025 Recap: Rheumatology News and Updates

ByVictoria Johnson

January 8th 2026

Rheumatology in 2025: Year in Review

Rheumatology in 2025: Year in Review

ByVictoria Johnson

January 6th 2026

Rheumatoid Arthritis in 2025: Year in Review

Rheumatoid Arthritis in 2025: Year in Review

ByVictoria Johnson

January 2nd 2026

Rosnilimab: A New Era of Upstream RA Disease Control, With Jonathan Graf, MD

Rosnilimab: A New Era of Upstream RA Disease Control, With Jonathan Graf, MD

ByJonathan Graf, MD

October 29th 2025

Gut Microbiome Modulation by Fiber Enhances RA Methotrexate Response, With Claire Daien, MD, PhD

Gut Microbiome Modulation by Fiber Enhances RA Methotrexate Response, With Claire Daien, MD, PhD

ByClaire Daien, MD, PhD

October 26th 2025